{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:19:10Z","timestamp":1788221950352,"version":"build-2803163510"},"reference-count":122,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014379","name":"Fundaci\u00f3n Unoentrecienmil","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014379","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Spanish Association Against Cancer Scientific Foundation","doi-asserted-by":"publisher","award":["PRDVA246268GIL"],"award-info":[{"award-number":["PRDVA246268GIL"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.blre.2026.101383","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T16:21:51Z","timestamp":1772641311000},"page":"101383","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Phenocopies in acute lymphoblastic leukemia: Redefining leukemia subtypes in the transcriptomic era"],"prefix":"10.1016","volume":"76","author":[{"given":"Jos\u00e9 Vicente","family":"Gil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Fuentes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel \u00c1ngel","family":"Verde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Miralles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"de las Heras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Barrag\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Llop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2026.101383_bb0005","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41525-022-00328-7","article-title":"Identification of phenocopies improves prediction of targeted therapy response over DNA mutations alone","volume":"7","author":"Bakhtiar","year":"2022","journal-title":"NPJ Genom Med"},{"issue":"10","key":"10.1016\/j.blre.2026.101383_bb0010","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/nrc1457","article-title":"Hallmarks of \u2018BRCAness\u2019 in sporadic cancers","volume":"4","author":"Turner","year":"2004","journal-title":"Nat Rev Cancer"},{"issue":"22","key":"10.1016\/j.blre.2026.101383_bb0015","doi-asserted-by":"crossref","first-page":"5007","DOI":"10.1200\/JCO.2005.09.111","article-title":"Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients","volume":"23","author":"Cappuzzo","year":"2005","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.blre.2026.101383_bb0020","doi-asserted-by":"crossref","first-page":"638","DOI":"10.3390\/cimb47080638","article-title":"Homologous recombination deficiency in ovarian and breast cancers: biomarkers, diagnosis, and treatment","volume":"47","author":"Shah","year":"2025","journal-title":"Curr Issues Mol Biol"},{"key":"10.1016\/j.blre.2026.101383_bb0025","article-title":"Identification of a gene signature closely related to immunosuppressive tumour microenvironment predicting prognosis of patients in EGFR mutant lung adenocarcinoma","volume":"11","author":"Li","year":"2021","journal-title":"Front Oncol"},{"issue":"11","key":"10.1016\/j.blre.2026.101383_bb0030","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.21037\/tcr-22-883","article-title":"Prediction of BRAF V600E variant from cancer gene expression data","volume":"11","author":"Kang","year":"2022","journal-title":"Transl Cancer Res"},{"issue":"2","key":"10.1016\/j.blre.2026.101383_bb0035","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/jnci\/djab169","article-title":"Homologous recombination deficiency alterations in colorectal cancer: clinical, molecular, and prognostic implications","volume":"114","author":"Moretto","year":"2022","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"10.1016\/j.blre.2026.101383_bb0040","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.blre.2026.101383_bb0045","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.blre.2026.101383_bb0050","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2026.101383_bb0055","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1038\/s41588-022-01159-z","article-title":"The genomic landscape of pediatric acute lymphoblastic leukemia","volume":"54","author":"Brady","year":"2022","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.blre.2026.101383_bb0060","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1470-2045(08)70339-5","article-title":"A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study","volume":"10","author":"Den Boer","year":"2000","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.blre.2026.101383_bb0065","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1056\/NEJMoa0808253","article-title":"Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia","volume":"360","author":"Mullighan","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2026.101383_bb0070","article-title":"Philadelphia-like genetic rearrangements in adults with B-cell ALL: refractoriness to chemotherapy and response to tyrosine kinase inhibitor in ABL class rearrangements","volume":"7","author":"Senapati","year":"2023","journal-title":"JCO Precis Oncol"},{"issue":"26","key":"10.1016\/j.blre.2026.101383_bb0075","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.1182\/blood-2009-09-245944","article-title":"Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic\/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia","volume":"115","author":"Harvey","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2026.101383_bb0080","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.clml.2024.08.005","article-title":"SOHO state of the art updates and next questions | approach to BCR::ABL1-like acute lymphoblastic leukemia","volume":"25","author":"Iacobucci","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"10.1016\/j.blre.2026.101383_bb0085","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1111\/bjh.19771","article-title":"Philadelphia-like B-cell acute lymphoblastic leukaemia: disease features and outcomes in the era of immunotherapy","volume":"205","author":"Ashouri","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2026.101383_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejcped.2025.100304","article-title":"From the bench of molecular understanding to the bedside of optimal therapy for BCR::ABL1 and ABL-class acute lymphoblastic leukemia in children and adolescents","volume":"6","author":"Tasian","year":"2025","journal-title":"EJC Paediatric Oncology"},{"issue":"4","key":"10.1016\/j.blre.2026.101383_bb0095","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1182\/blood-2011-12-389932","article-title":"Aberrant STAT5 and PI3K\/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia","volume":"120","author":"Tasian","year":"2012","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.blre.2026.101383_bb0100","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1200\/JCO.2017.74.3617","article-title":"IKZF1plus defines a new minimal residual disease-dependent very-poor prognostic profile in pediatric B-cell precursor acute lymphoblastic leukemia","volume":"36","author":"Stanulla","year":"2018","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.blre.2026.101383_bb0105","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1182\/bloodadvances.2018025718","article-title":"Validation of the United Kingdom copy-number alteration classifier in 3239 children with B-cell precursor ALL","volume":"3","author":"Hamadeh","year":"2019","journal-title":"Blood Adv"},{"issue":"19","key":"10.1016\/j.blre.2026.101383_bb0110","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1182\/blood-2017-06-743252","article-title":"Philadelphia chromosome-like acute lymphoblastic leukemia","volume":"130","author":"Tasian","year":"2017","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.blre.2026.101383_bb0115","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","article-title":"Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia","volume":"371","author":"Roberts","year":"2014","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.blre.2026.101383_bb0120","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1182\/blood-2016-12-758979","article-title":"Targetable kinase gene fusions in high-risk B-ALL: a study from the Children\u2019s Oncology Group","volume":"129","author":"Reshmi","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2026.101383_bb0125","doi-asserted-by":"crossref","first-page":"4618","DOI":"10.18632\/oncotarget.13492","article-title":"Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia","volume":"8","author":"Boer","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.blre.2026.101383_bb0130","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood.2023023153","article-title":"How I treat Philadelphia chromosome-like acute lymphoblastic leukemia in children, adolescents, and young adults","volume":"145","author":"Tran","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101383_bb0135","article-title":"Tyrosine kinase inhibitors during frontline therapy in adults with acute lymphoblastic leukemia with ABL-class rearrangements","author":"Braish","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.blre.2026.101383_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2022.106925","article-title":"Efficacy of ruxolitinib in acute lymphoblastic leukemia: a systematic review","volume":"121","author":"Ko\u0142odrubiec","year":"2022","journal-title":"Leuk Res"},{"issue":"10","key":"10.1016\/j.blre.2026.101383_bb0145","doi-asserted-by":"crossref","first-page":"5521","DOI":"10.1007\/s00277-025-06596-4","article-title":"Treatment of EPOR-rearranged acute lymphoblastic leukemia with ruxolitinib: case reports and review of the literature","volume":"104","author":"Dai","year":"2025","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.blre.2026.101383_bb0150","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3324\/haematol.2022.280879","article-title":"BCL6 inhibition ameliorates resistance to ruxolitinib in CRLF2-rearranged acute lymphoblastic leukemia","volume":"108","author":"Tsuzuki","year":"2023","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.blre.2026.101383_bb0160","doi-asserted-by":"crossref","DOI":"10.1186\/s43046-022-00126-3","article-title":"St. Jude total therapy studies from I to XVII for childhood acute lymphoblastic leukemia: a brief review","volume":"34","author":"Omar","year":"2022","journal-title":"J Egypt Natl Canc Inst"},{"issue":"12","key":"10.1016\/j.blre.2026.101383_bb0165","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1007\/s00277-023-05456-3","article-title":"The role of ruxolitinib treatment in JAK-mutated Ph-like acute lymphoblastic leukemia","volume":"102","author":"Candan","year":"2023","journal-title":"Ann Hematol"},{"issue":"9","key":"10.1016\/j.blre.2026.101383_bb0175","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1038\/s41375-024-02329-0","article-title":"Integration of genetics and MRD to define low risk patients with B-cell precursor acute lymphoblastic leukaemia with intermediate MRD levels at the end of induction","volume":"38","author":"Moorman","year":"2024","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.blre.2026.101383_bb0190","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1038\/s41591-019-0542-z","article-title":"Resistance to TRK inhibition mediated by convergent MAPK pathway activation","volume":"25","author":"Cocco","year":"2019","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.blre.2026.101383_bb0200","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa2312948","article-title":"Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults","volume":"391","author":"Litzow","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2026.101383_bb0205","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11790","article-title":"Identification of ETV6-RUNX1-like and DUX4-rearranged subtypes in paediatric B-cell precursor acute lymphoblastic leukaemia","volume":"7","author":"Lilljebj\u00f6rn","year":"2016","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.blre.2026.101383_bb0210","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/gcc.22464","article-title":"ETV6\/RUNX1-like acute lymphoblastic leukemia: A novel B-cell precursor leukemia subtype associated with the CD27\/CD44 immunophenotype","volume":"56","author":"Zaliova","year":"2017","journal-title":"Genes Chromosomes Cancer"},{"issue":"50","key":"10.1016\/j.blre.2026.101383_bb0215","doi-asserted-by":"crossref","first-page":"E11711","DOI":"10.1073\/pnas.1814397115","article-title":"Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1,223 cases","volume":"115","author":"Li","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.blre.2026.101383_bb0220","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41588-018-0315-5","article-title":"PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia","volume":"51","author":"Gu","year":"2019","journal-title":"Nat Genet"},{"issue":"12","key":"10.1016\/j.blre.2026.101383_bb0225","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1002\/cam4.3928","article-title":"RAG1 co-expression signature identifies ETV6-RUNX1-like B-cell precursor acute lymphoblastic leukemia in children","volume":"10","author":"Chen","year":"2021","journal-title":"Cancer Med"},{"issue":"17","key":"10.1016\/j.blre.2026.101383_bb0230","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1182\/blood-2009-10-251413","article-title":"Acquisition of genome-wide copy number alterations in monozygotic twins with acute lymphoblastic leukemia","volume":"115","author":"Bateman","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2026.101383_bb0235","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1182\/blood-2011-02-338848","article-title":"Modeling the evolution of ETV6-RUNX1-induced B-cell precursor acute lymphoblastic leukemia in mice","volume":"118","author":"van der Weyden","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2026.101383_bb0240","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/ng.2874","article-title":"RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia","volume":"46","author":"Papaemmanuil","year":"2014","journal-title":"Nat Genet"},{"issue":"21","key":"10.1016\/j.blre.2026.101383_bb0245","doi-asserted-by":"crossref","first-page":"35445","DOI":"10.18632\/oncotarget.16367","article-title":"Pathogenesis of ETV6\/RUNX1-positive childhood acute lymphoblastic leukemia and mechanisms underlying its relapse","volume":"8","author":"Sun","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.blre.2026.101383_bb0250","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/s41375-022-01799-4","article-title":"Integrative genomic analysis of childhood acute lymphoblastic leukaemia lacking a genetic biomarker in the UKALL2003 clinical trial","volume":"37","author":"Schwab","year":"2023","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.blre.2026.101383_bb0255","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1005262","article-title":"Germline ETV6 mutations confer susceptibility to acute lymphoblastic leukemia and thrombocytopenia","volume":"11","author":"Topka","year":"2015","journal-title":"PLoS Genet"},{"issue":"16","key":"10.1016\/j.blre.2026.101383_bb0260","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/S1470-2045(15)00369-1","article-title":"Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukaemia: a systematic genetic study","volume":"16","author":"Moriyama","year":"2015","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.blre.2026.101383_bb0265","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1182\/blood.2020006164","article-title":"Molecular basis of ETV6-mediated predisposition to childhood acute lymphoblastic leukemia","volume":"137","author":"Nishii","year":"2021","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2026.101383_bb0270","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/2643-3230.BCD-20-0229","article-title":"Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease-directed therapy","volume":"2","author":"Jeha","year":"2021","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.blre.2026.101383_bb0275","article-title":"The clinical and genetic features of ETV6\/RUNX1-like acute lymphoblastic leukemia in pediatric: a multicenter retrospective study","author":"He","year":"2024","journal-title":"Research Square"},{"issue":"5","key":"10.1016\/j.blre.2026.101383_bb0280","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000875","article-title":"The prognostic effect of IKZF1 deletions in ETV6::RUNX1 and high hyperdiploid childhood acute lymphoblastic leukemia","volume":"7","author":"\u00d8stergaard","year":"2023","journal-title":"Hemasphere"},{"issue":"2","key":"10.1016\/j.blre.2026.101383_bb0285","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3324\/haematol.2022.281059","article-title":"IL1RAP is expressed in several subtypes of pediatric acute lymphoblastic leukemia and can be used as a target to eliminate ETV6::RUNX1-positive leukemia cells in preclinical models","volume":"108","author":"\u00c5gerstam","year":"2023","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.blre.2026.101383_bb0290","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.3324\/haematol.2018.204974","article-title":"Genomic landscape of pediatric B-other acute lymphoblastic leukemia in a consecutive European cohort","volume":"104","author":"Zaliova","year":"2019","journal-title":"Haematologica"},{"issue":"21","key":"10.1016\/j.blre.2026.101383_bb0295","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/bloodadvances.2021005318","article-title":"A novel class of ZNF384 aberrations in acute leukemia","volume":"5","author":"Zaliova","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2026.101383_bb0300","doi-asserted-by":"crossref","DOI":"10.1177\/10732748231182787","article-title":"ZNF384-related fusion genes in acute lymphoblastic leukemia","volume":"30","author":"Zhu","year":"2023","journal-title":"Cancer Control"},{"issue":"5","key":"10.1016\/j.blre.2026.101383_bb0305","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/cyto.b.22086","article-title":"Immunophenotypic characteristics of ZNF384 rearrangement compared with BCR-ABL1, KMT2A rearrangement, and other adult B-cell precursor acute lymphoblastic leukemia","volume":"102","author":"Wang","year":"2022","journal-title":"Cytometry B Clin Cytom"},{"issue":"11","key":"10.1016\/j.blre.2026.101383_bb0310","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1038\/s41375-021-01199-0","article-title":"Clinical characteristics and outcomes of B-ALL with ZNF384 rearrangements: a retrospective analysis by the Ponte di Legno Childhood ALL Working Group","volume":"35","author":"Hirabayashi","year":"2021","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.blre.2026.101383_bb0315","doi-asserted-by":"crossref","DOI":"10.1002\/ccr3.71001","article-title":"TAF15::ZNF384 mixed phenotype acute leukemia with complex karyotype: case report with B-ALL induction, blinatumomab bridging to allogeneic transplant and literature review","volume":"13","author":"Blain","year":"2025","journal-title":"Clin Case Reports"},{"issue":"9","key":"10.1016\/j.blre.2026.101383_bb0320","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27265","article-title":"Myeloid lineage switch following chimeric antigen receptor T-cell therapy in a patient with TCF3-ZNF384 fusion-positive B-lymphoblastic leukemia","volume":"65","author":"Oberley","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"10.1016\/j.blre.2026.101383_bb0325","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23074019","article-title":"Lineage conversion in pediatric B-cell precursor acute leukemia under Blinatumomab therapy","volume":"23","author":"Semchenkova","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.blre.2026.101383_bb0330","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1038\/s41467-022-33143-w","article-title":"Epigenetic activation of the FLT3 gene by ZNF384 fusion confers a therapeutic susceptibility in acute lymphoblastic leukemia","volume":"13","author":"Zhao","year":"2022","journal-title":"Nat Commun"},{"issue":"14","key":"10.1016\/j.blre.2026.101383_bb0335","doi-asserted-by":"crossref","first-page":"4093","DOI":"10.1182\/bloodadvances.2021005894","article-title":"ALLSorts: an RNA-Seq subtype classifier for B-cell acute lymphoblastic leukemia","volume":"6","author":"Schmidt","year":"2022","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.blre.2026.101383_bb0340","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000939","article-title":"The gene expression classifier ALLCatchR identifies B-cell precursor ALL subtypes and underlying developmental trajectories across age","volume":"7","author":"Beder","year":"2023","journal-title":"Hemasphere"},{"issue":"7","key":"10.1016\/j.blre.2026.101383_bb0345","first-page":"1744","article-title":"MD-ALL: an integrative platform for molecular diagnosis of B-ALL","volume":"109","author":"Hu","year":"2024","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.blre.2026.101383_bb0350","doi-asserted-by":"crossref","first-page":"921","DOI":"10.21873\/anticanres.17479","article-title":"Cryptic rearrangement of the KMT2A gene in a B-cell acute lymphoblastic leukemia","volume":"45","author":"Brunetti","year":"2025","journal-title":"Anticancer Res"},{"issue":"5","key":"10.1016\/j.blre.2026.101383_bb0355","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/s41375-023-01877-1","article-title":"The KMT2A recombinome of acute leukemias in 2023","volume":"37","author":"Meyer","year":"2023","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.blre.2026.101383_bb0360","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/s41591-022-01720-7","article-title":"Single-cell transcriptomics reveals a distinct developmental state of KMT2A-rearranged infant B-cell acute lymphoblastic leukemia","volume":"28","author":"Khabirova","year":"2022","journal-title":"Nat Med"},{"issue":"7953","key":"10.1016\/j.blre.2026.101383_bb0365","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","article-title":"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mut leukaemia","volume":"615","author":"Issa","year":"2023","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.blre.2026.101383_bb0370","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3390\/hematolrep16020024","article-title":"A 2024 update on Menin inhibitors. A new class of target agents against KMT2A-rearranged and NPM1-mutated acute myeloid leukemia","volume":"16","author":"Candoni","year":"2024","journal-title":"Hematol Rep"},{"issue":"49","key":"10.1016\/j.blre.2026.101383_bb0375","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2211429119","article-title":"Transcriptome-based molecular subtypes and differentiation hierarchies improve the classification framework of acute myeloid leukemia","volume":"119","author":"Cheng","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"10.1016\/j.blre.2026.101383_bb0380","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1182\/blood.2023021359","article-title":"Acute myeloid leukemias with UBTF tandem duplications are sensitive to menin inhibitors","volume":"143","author":"Barajas","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101383_bb0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.exphem.2025.105247","article-title":"KMT2A-rearranged leukemia: from mechanism to drug development","volume":"151","author":"Ernst","year":"2025","journal-title":"Exp Hematol"},{"issue":"1","key":"10.1016\/j.blre.2026.101383_bb0390","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00428-022-03448-8","article-title":"International consensus classification of acute lymphoblastic leukemia\/lymphoma","volume":"482","author":"Duffield","year":"2023","journal-title":"Virchows Arch"},{"issue":"6","key":"10.1016\/j.blre.2026.101383_bb0395","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1182\/blood.2021012806","article-title":"The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML","volume":"139","author":"Heikamp","year":"2022","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2026.101383_bb0400","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/S1470-2045(24)00386-3","article-title":"Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial","volume":"25","author":"Wang","year":"2024","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.blre.2026.101383_bb0405","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S1535-6108(03)00003-5","article-title":"Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification","volume":"3","author":"Armstrong","year":"2003","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.blre.2026.101383_bb0410","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2004-06-2498","article-title":"FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression","volume":"105","author":"Brown","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101383_bb0415","article-title":"Advancements in targeted therapies for acute myeloid leukemia","volume":"87","author":"Connor","year":"2025","journal-title":"Curr Opin Pharmacol"},{"issue":"17","key":"10.1016\/j.blre.2026.101383_bb0420","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJMoa2214171","article-title":"Blinatumomab added to chemotherapy in infant lymphoblastic leukemia","volume":"388","author":"van der Sluis","year":"2023","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.blre.2026.101383_bb0425","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1182\/bloodadvances.2019001008","article-title":"The application of RNA sequencing for the diagnosis and genomic classification of pediatric acute lymphoblastic leukemia","volume":"4","author":"Brown","year":"2020","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.blre.2026.101383_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.labinv.2025.104201","article-title":"Integrative genetic and transcriptomic subtyping improves prognosis prediction in B-lineage acute lymphoblastic leukemia","volume":"105","author":"Benjamin","year":"2025","journal-title":"Lab Invest"},{"issue":"11","key":"10.1016\/j.blre.2026.101383_bb0435","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1038\/s41416-025-03204-0","article-title":"Benchmarking standard-of-care and emerging genomic approaches to enhance diagnosis in pediatric acute lymphoblastic leukemia","volume":"133","author":"Gil","year":"2025","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.blre.2026.101383_bb0440","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/bloodadvances.2021005634","article-title":"Whole-transcriptome analysis in acute lymphoblastic leukemia: a report from the DFCI ALL Consortium Protocol 16-001","volume":"6","author":"Tran","year":"2022","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.blre.2026.101383_bb0445","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1111\/bjh.20056","article-title":"RNA-sequencing: a reliable tool to unveil transcriptional landscape of paediatric B-other acute lymphoblastic leukaemia","volume":"206","author":"Vicente-Garc\u00e9s","year":"2025","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2026.101383_bb0450","article-title":"A study protocol for validation and implementation of whole-genome and -transcriptome sequencing as a comprehensive precision diagnostic test in acute leukemias","volume":"9","author":"Berglund","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.blre.2026.101383_bb0455","doi-asserted-by":"crossref","DOI":"10.1017\/pcm.2023.3","article-title":"Genomic medicine Sweden (GMS). Building a precision medicine infrastructure at a national level: the Swedish experience","volume":"1","author":"Edsj\u00f6","year":"2023","journal-title":"Camb Prisms Precis Med"},{"key":"10.1016\/j.blre.2026.101383_bb0460","article-title":"Error reduction in leukemia machine learning classification with conformal prediction","volume":"9","author":"Lysenkova Wiklander","year":"2025","journal-title":"JCO Clin Cancer Inform"},{"issue":"14","key":"10.1016\/j.blre.2026.101383_bb0465","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1182\/blood.2023022919","article-title":"Genetic subtypes of B-cell acute lymphoblastic leukemia in adults","volume":"145","author":"Passet","year":"2025","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2026.101383_bb0470","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/bjh.17959","article-title":"Precursor B-cell acute lymphoblastic leukaemia-a global view","volume":"196","author":"Biondi","year":"2022","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.blre.2026.101383_bb0475","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41416-025-02958-x","article-title":"ALLTogether recommendations for biobanking samples from patients with acute lymphoblastic leukaemia: a modified Delphi study","volume":"132","author":"Trinquand","year":"2025","journal-title":"Br J Cancer"},{"issue":"27","key":"10.1016\/j.blre.2026.101383_bb0480","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1200\/JCO.2014.55.4105","article-title":"Outcomes of children with BCR-ABL1\u2013like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease","volume":"32","author":"Roberts","year":"2014","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.blre.2026.101383_bb0485","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s00277-023-05241-2","article-title":"Philadelphia-like acute lymphoblastic leukemia: the journey from molecular background to the role of bone marrow transplant-review article","volume":"102","author":"Alghandour","year":"2023","journal-title":"Ann Hematol"},{"issue":"17","key":"10.1016\/j.blre.2026.101383_bb0490","doi-asserted-by":"crossref","first-page":"4936","DOI":"10.1182\/bloodadvances.2022007597","article-title":"Outcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALL","volume":"6","author":"Aldoss","year":"2022","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.blre.2026.101383_bb0495","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.jtct.2024.09.020","article-title":"A multicenter analysis of allogeneic transplant outcomes in adults with Philadelphia-like B-cell acute lymphoblastic leukemia in first complete remission","volume":"30","author":"Rahman","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"23","key":"10.1016\/j.blre.2026.101383_bb0500","doi-asserted-by":"crossref","first-page":"5226","DOI":"10.1182\/bloodadvances.2021004895","article-title":"Distinct clinical characteristics of DUX4- and PAX5-altered childhood B-lymphoblastic leukemia","volume":"5","author":"Li","year":"2021","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.blre.2026.101383_bb0505","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1038\/s41375-025-02758-5","article-title":"DUX4-rearranged B-ALL: deciphering a biological and clinical conundrum","volume":"39","author":"Bakewell","year":"2025","journal-title":"Leukemia"},{"issue":"29","key":"10.1016\/j.blre.2026.101383_bb0510","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1200\/JCO.23.02238","article-title":"Genomic determinants of outcome in acute lymphoblastic leukemia","volume":"42","author":"Chang","year":"2024","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.blre.2026.101383_bb0515","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1182\/blood.V122.21.3884.3884","article-title":"Core binding factor acute myeloid leukemia in pediatric patients enrolled in the AIEOP AML 2002\/01 trial: the impact of minimal residual disease on patient outcome","volume":"122","author":"Pigazzi","year":"2013","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2026.101383_bb0520","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3390\/cancers17050801","article-title":"Tumor-agnostic therapies in practice: challenges, innovations, and future perspectives","volume":"17","author":"Wu","year":"2025","journal-title":"Cancers (Basel)."},{"issue":"11","key":"10.1016\/j.blre.2026.101383_bb0525","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.32604\/or.2025.067791","article-title":"Advances in tissue-agnostic targeting in cancer therapeutics: current approvals, challenges, and future directions","volume":"33","author":"Rubinstein","year":"2025","journal-title":"Oncol Res"},{"issue":"11","key":"10.1016\/j.blre.2026.101383_bb0530","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.3324\/haematol.2020.247031","article-title":"Pediatric acute lymphoblastic leukemia","volume":"105","author":"Inaba","year":"2020","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.blre.2026.101383_bb0535","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.blre.2026.101383_bb0540","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1112168","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis","volume":"367","author":"Sandborn","year":"2012","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.blre.2026.101383_bb0545","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.clml.2025.05.013","article-title":"A phase I\/II trial of ruxolitinib with chemotherapy for patients with relapsed and\/or refractory Philadelphia-like acute lymphoblastic leukemia","volume":"25","author":"Goulart","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"10.1016\/j.blre.2026.101383_bb0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100164","article-title":"The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM-SIAPEC-IAP-SIBioC-SIC-SIF Italian Scientific Societies","volume":"6","author":"Russo","year":"2021","journal-title":"ESMO Open"},{"issue":"4","key":"10.1016\/j.blre.2026.101383_bb0555","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/s41375-024-02137-6","article-title":"Mapping AML heterogeneity - multi-cohort transcriptomic analysis identifies novel clusters and divergent ex-vivo drug responses","volume":"38","author":"Severens","year":"2024","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.blre.2026.101383_bb0560","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1038\/s41467-022-32266-4","article-title":"Multi-omics analysis defines highly refractory RAS burdened immature subgroup of infant acute lymphoblastic leukemia","volume":"13","author":"Isobe","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.blre.2026.101383_bb0565","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/MOP.0000000000001316","article-title":"Novel therapies for pediatric acute lymphoblastic leukemia","volume":"36","author":"Graff","year":"2024","journal-title":"Curr Opin Pediatr"},{"key":"10.1016\/j.blre.2026.101383_bb0570","doi-asserted-by":"crossref","DOI":"10.1200\/PO-24-00788","article-title":"Challenging Conventional Diagnostic Methods by Comprehensive Molecular Diagnostics: A Nationwide Prospective Comparison in Children With ALL","author":"Boer","year":"2025","journal-title":"JCO Precis Oncol"},{"issue":"10","key":"10.1016\/j.blre.2026.101383_bb0575","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.jmoldx.2021.07.013","article-title":"Practical considerations for using RNA sequencing in management of B-lymphoblastic leukemia: Malaysia-Singapore acute lymphoblastic leukemia 2020 implementation strategy","volume":"23","author":"Ni Chin","year":"2021","journal-title":"J Mol Diagn"},{"issue":"1","key":"10.1016\/j.blre.2026.101383_bb0580","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-06485-7","article-title":"Clinical cancer genomic profiling by three-platform sequencing of whole genome, whole exome and transcriptome","volume":"9","author":"Rusch","year":"2018","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.blre.2026.101383_bb0585","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1158\/2159-8290.CD-20-1230","article-title":"St. jude cloud: a pediatric cancer genomic data-sharing ecosystem","volume":"11","author":"McLeod","year":"2021","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.blre.2026.101383_bb0590","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jmoldx.2023.09.013","article-title":"Transcriptome sequencing allows comprehensive genomic characterization of pediatric B-acute lymphoblastic leukemia in an academic clinical laboratory","volume":"26","author":"Hu","year":"2024","journal-title":"J Mol Diagn"},{"issue":"1","key":"10.1016\/j.blre.2026.101383_bb0595","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/s41698-025-00993-8","article-title":"Augmenting precision medicine via targeted RNA-Seq detection of expressed mutations","volume":"9","author":"Li","year":"2025","journal-title":"NPJ Precis Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2026.101383_bb0600","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1182\/blood-2023-190495","article-title":"Feasibility and outcome of post-induction therapy incorporating Dasatinib for patients with newly diagnosed ABL-class fusion B-lymphoblastic leukemia (ABL-class fusion B-ALL): children\u2019s oncology group AALL1131","volume":"142","author":"Salzer","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2026.101383_bb0605","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1182\/hematology.2022000357","article-title":"Clinical screening for Ph-like ALL and the developing role of TKIs","volume":"2022","author":"Tran","year":"2022","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"5","key":"10.1016\/j.blre.2026.101383_bb0610","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/bjh.17093","article-title":"Adjuvant tyrosine kinase inhibitor therapy improves outcome for children and adolescents with acute lymphoblastic leukaemia who have an ABL-class fusion","volume":"191","author":"Moorman","year":"2020","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.blre.2026.101383_bb0615","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.3324\/haematol.2019.231720","article-title":"Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols","volume":"105","author":"Cario","year":"2020","journal-title":"Haematologica"},{"issue":"16","key":"10.1016\/j.blre.2026.101383_bb0620","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1182\/blood.2019001244","article-title":"Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements","volume":"134","author":"Tanasi","year":"2019","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2026.101383_bb0625","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.3390\/ijms23094574","article-title":"Multi-cohort transcriptomic subtyping of B-cell acute lymphoblastic leukemia","volume":"23","author":"M\u00e4kinen","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.blre.2026.101383_bb0630","article-title":"Multimodal classification of molecular subtypes in pediatric acute lymphoblastic leukemia","volume":"7","author":"Krali","year":"2023","journal-title":"NPJ Precis Oncol"},{"issue":"1","key":"10.1016\/j.blre.2026.101383_bb0635","article-title":"RanBALL: an ensemble random projection model for identifying B-ALL subtypes","volume":"17","author":"Li","year":"2025","journal-title":"Cancers (Basel)"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X26000226?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X26000226?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:11:53Z","timestamp":1788221513000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X26000226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":122,"alternative-id":["S0268960X26000226"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2026.101383","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phenocopies in acute lymphoblastic leukemia: Redefining leukemia subtypes in the transcriptomic era","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2026.101383","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101383"}}